The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Open accessAbstract
BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks). Coprimary end points were rates of overall and progression-free survival. Secondary end points included the response rate, response duration, and safety. A final analysis was planned after 196 deaths and an interim analysis after 98 deaths. RESULTS: At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. In the interim analysis for overall survival and final analysis for progression-free survival, vemurafenib was associated with a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P<0.001 for both comparisons). After review of the interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended. Response rates were 48% for vemurafenib and 5% for dacarbazine. Common adverse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects. CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vemurafenib, a selective oral inhibitor of the BRAF V600 kinase, achieved an approximately 50% response and improved survival among metastatic melanoma patients with the BRAF V600E mutation [97].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [97]
In the citing paper
“Maturation of survival data also increased the ESMO-MCBS score of vemurafenib in the treatment of metastatic melanoma [116, 117] from ESMO-MCBS 3 based on PFS to 4, based on OS.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationJemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,653
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationDistinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,875
Self-citationRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Flagged first, then by citations
Research works printed but not linked: 1
- Kumar R, 2003, Clin Cancer Res, 9, 3362
Cited by
Sorted by citations
Items 301–400 of 1,053
The powerful world of antisense oligonucleotides: From bench to bedside
Quéméner, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M. (2020) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1594 · Cited by 284
“…kinases, such as specific inhibitors of the constitutively active form of the BRAF kinase (BRAF-V600) in BRAF-V600 mutated metastatic melanoma (Chapman et al., 2011) The use of blocking antibodies specific for an oncogenic pathway has also resulted in therapeutic success (antiEGFR antibody in…”
BackgroundTargeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S. R., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente‐Macías, Á., Baillache, D. J., Croke, S., & Unciti‐Broceta, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 294
Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K. N., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02767 · Cited by 301
Codon-specific translation reprogramming promotes resistance to targeted therapy
Rapino, F., Delaunay, S., Rambow, F., Zhou, Z., Tharun, L., De Tullio, P., Sin, O., Shostak, K., Schmitz, S., Piepers, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0243-7 · Cited by 271
Yaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2779 · Cited by 276
Ipilimumab and radiation therapy for melanoma brain metastases
Silk, A. W., Bassetti, M. F., West, B. T., Tsien, C. I., & Lao, C. D. (2013) · Cancer Medicine · doi:10.1002/cam4.140 · Cited by 280
Larkin, J., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Espinosa, E., Garbe, C., Chiarion‐Sileni, V., Gogas, H. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70051-8 · Cited by 282
Self-citationThe genomic landscape of breast cancer and its interaction with host immunity
Luen, S. J., Virassamy, B., Savas, P. S., Salgado, R., & Loi, S. (2016) · The Breast · doi:10.1016/j.breast.2016.07.015 · Cited by 279
Immunotherapy in melanoma: Recent advances and future directions
Franklin, C., Livingstone, E., Roesch, A., Schilling, B., & Schadendorf, D. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.145 · Cited by 286
Self-citationKirkwood, J. M., Bastholt, L., Robert, C., Sosman, J. A., Larkin, J., Hersey, P., Middleton, M. R., Cantarini, M., Zazulina, V., Kemsley, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1491 · Cited by 276
Self-citationImmune system and melanoma biology: a balance between immunosurveillance and immune escape
Passarelli, A. M., Mannavola, F., Stucci, L. S., Tucci, M., & Silvestris, F. (2017) · Oncotarget · doi:10.18632/oncotarget.22190 · Cited by 287
Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers
Reimand, J., & Bader, G. D. (2013) · Molecular Systems Biology · doi:10.1038/msb.2012.68 · Cited by 274
Pritchard, C. C., Salipante, S. J., Koehler, K. M., Smith, C., Scroggins, S. M., Wood, B. L., Wu, D., Lee, M. K., Dintzis, S. M., Adey, A., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.08.004 · Cited by 277
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
Ramos, P. M., & Bentires‐Alj, M. (2014) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 287
Many ways to resistance: How melanoma cells evade targeted therapies
Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.02.002 · Cited by 289
Renfro, L. A., & Sargent, D. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw413 · Cited by 281
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3498 · Cited by 275
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T. J., Mok, S., Cass, A. A., Haynes, N. M., Kinross, K. M., Yagita∥, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 274
Self-citationRetractedGrob, J., Amonkar, M. M., Karaszewska, B., Schachter, J., Dummer, R., Mackiewicz, A. A., Stroyakovskiy, D., Drucis, K., Grange, F., Chiarion‐Sileni, V., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00087-x · Cited by 270
Self-citationA Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Cancer of Unknown Primary Site
Varadhachary, G. R., & Raber, M. N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1303917 · Cited by 267
Adoptive Immunotherapy for Cancer or Viruses
Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M. D., Zhao, Y., & June, C. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120136 · Cited by 267
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 273
Self-citationActin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation
Kim, M. H., Kim, J., Hong, H., Lee, J. J.-K., Lee, J., Jung, E., & Kim, J. (2015) · The EMBO Journal · doi:10.15252/embj.201592081 · Cited by 270
The kinome 'at large' in cancer
Fleuren, E. D. G., Zhang, L., Wu, J., & Daly, R. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2015.18 · Cited by 268
MEK in cancer and cancer therapy
Neuzillet, C., Tijeras‐Raballand, A., de Mestier, L., Cros, J. F., Faivre, S. J., & Raymond, É. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.001 · Cited by 273
The cancer genome atlas pan-cancer analysis project
Mills, G. B., Mills Shaw, K. R., Shmulevich, I., Stuart, J. M., Ellrott, K., Sander, C., The Cancer Genome Atlas Research Network, Collisson, E. A., Ozenberger, B. A., & Weinstein, J. N. (2013) · Europe PMC (PubMed Central) · doi:10.17615/670y-yr53 · Cited by 265
Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B. A. G., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., Testori, A., Lorigan, P. C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx339 · Cited by 269
Self-citationMEK and the inhibitors: from bench to bedside
Akinleye, A., Furqan, M., Mukhi, N., Ravella, P., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-27 · Cited by 291
Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation
Kleinschmidt-DeMasters, B. K., Aisner, D. L., Birks, D. K., & Foreman, N. K. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827f9c5e · Cited by 261
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Cooper, Z. A., Juneja, V. R., Sage, P. T., Frederick, D. T., Piris, A., Mitra, D., Lo, J. A., Hodi, F. S., Freeman, G. J., Bosenberg, M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0215 · Cited by 264
Self-citationRheault, T., Stellwagen, J. C., Adjabeng, G. M., Hornberger, K. R., Petrov, K. G., Waterson, A. G., Dickerson, S. H., Mook, R. A., Laquerre, S. G., King, A. J., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000063 · Cited by 256
Precision oncology: origins, optimism, and potential
Prasad, V. K., Fojo, T., & Brada, M. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00620-8 · Cited by 257
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R. A., Shao, W., & Sellers, W. R. (2015) · EMBO Reports · doi:10.15252/embr.201439949 · Cited by 264
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K., Marzo, A. M. D., Hammond, M. E. H., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 262
BRAF Inhibition in Refractory Hairy-Cell Leukemia
Dietrich, S., Glimm, H., Andrulis, M., Kalle, C. V., Ho, A. D., & Zenz, T. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1202124 · Cited by 252
Simeone, E., Gentilcore, G., Giannarelli, D., Grimaldi, A. M., Caracò, C., Curvietto, M., Esposito, A., Paone, M., Palla, M., Cavalcanti, E., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1545-8 · Cited by 253
Self-citationCancer biomarkers: selecting the right drug for the right patient
Kelloff, G. J., & Sigman, C. C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3651 · Cited by 256
YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
Kim, M. H., Kim, C. G., Kim, S.-K., Shin, S. J., Choe, E. A., Park, S.-H., Shin, E.-C., & Kim, J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0320 · Cited by 241
Tsimberidou, A. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2861-1 · Cited by 268
Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma
Wu, R. C. H., Forget, M., Chacon, J. A., Bernatchez, C., Haymaker, C., Chen, J. Q., Hwu, P., & Radvanyi, L. G. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824d4465 · Cited by 249
P21 activated kinase signaling in cancer
Rane, C. K., & Minden, A. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.006 · Cited by 247
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
Chaikuad, A., Tacconi, E. M., Zimmer, J., Liang, Y., Gray, N. S., Tarsounas, M., & Knapp, S. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1629 · Cited by 250
Keratoacanthoma (KA): An update and review
Kwiek, B., & Schwartz, R. A. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.11.033 · Cited by 247
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Ihle, M. A., Fassunke, J., König, K., Grünewald, I., Schlaak, M. S., Kreuzberg, N., Tietze, L., Schildhaus, H., Büttner, R., & Merkelbach‐Bruse, S. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-13 · Cited by 251
Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
Levy, J. M. M., Thompson, J. C., Griesinger, A. M., Amani, V. M., Donson, A. M., Birks, D. K., Morgan, M. J., Mirsky, D. M., Handler, M. H., Foreman, N. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0049 · Cited by 245
Targeting Oncogenic BRAF: Past, Present, and Future
Zaman, A., Wu, W., & Bivona, T. G. (2019) · Cancers · doi:10.3390/cancers11081197 · Cited by 252
“These clinical successes were facilitated by the mechanistic work that suggested the role of EGFR-mediated MAPK reactivation in certain BRAF inhibitor-treated BRAFV600E-positive tumors [41,61,62].”
BackgroundInfluentialThe Role of the PI3K-AKT Pathway in Melanoma
Davies, M. A. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824d448c · Cited by 240
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Abel, E. V., Basile, K. J., Kugel, C. H., Witkiewicz, A. K., Le, K., Amaravadi, R. K., Karakousis, G. C., Xu, X., Xu, W., Schuchter, L. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65780 · Cited by 249
Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
Rosenberg, S. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003634 · Cited by 249
Systemic cancer therapy: achievements and challenges that lie ahead
Palumbo, M. O., Kavan, P., Miller, W. H., Panasci, L., Assouline, S. E., Johnson, N., Cohen, V., Patenaude, F., Pollak, M., Jagoe, R. T., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00057 · Cited by 257
Physicians' Attitudes About Multiplex Tumor Genomic Testing
Gray, S. W., Hicks-Courant, K., Cronin, A. M., Rollins, B. J., & Weeks, J. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.4298 · Cited by 244
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Moeini, A., Sia, D., Bardeesy, N. M., Mazzaferro, V., & Llovet, J. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3296 · Cited by 246
Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”
Pflugfelder, A., Kochs, C., Blum, A., Capellaro, M., Czeschik, J. C., Dettenborn, T., Dill, D., Dippel, E., Eigentler, T., Feyer, P. C., et al. (2013) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.12113_suppl · Cited by 240
Self-citationPersonalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
de Castro, D. G., Clarke, P. A., Al‐Lazikani, B., & Workman, P. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.237 · Cited by 237
Ahmed, K. A., Stallworth, D. G., Kim, Y., Johnstone, P. A. S., Harrison, L. B., Caudell, J. J., Yu, H., Etame, A. B., Weber, J. S., & Gibney, G. T. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv622 · Cited by 240
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Sullivan, R. J., Hamid, O., Gonzalez, R. C., Infante, J. R., Patel, M. R., Hodi, F. S., Lewis, K. D., Tawbi, H. A., Hernandez, G., Wongchenko, M. J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0474-7 · Cited by 242
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Wheler, J. J., Jankú, F., Naing, A., Li, Y., Stephen, B., Zinner, R., Subbiah, V., Fu, S., Karp, D. D., Falchook, G. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3043 · Cited by 241
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022
Horbinski, C., Nabors, B., Portnow, J., Baehring, J. M., Bhatia, A., Bloch, O. G., Brem, S. S., Butowski, N. A., Cannon, D. M., Chao, S. T., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0002 · Cited by 246
Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
Callahan, M. K., Rampal, R. K., Harding, J. J., Klimek, V. M., Chung, Y. R., Merghoub, T., Wolchok, J. D., Solit, D. B., Rosen, N. X., Abdel-Wahab, O. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208958 · Cited by 243
Self-citationGermann, U. A., Furey, B. F., Markland, W., Hoover, R. R., Aronov, A. M., Roix, J. J., Hale, M. R., Boucher, D. M., Sorrell, D. A., Martínez-Botella, G., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0456 · Cited by 240
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Heinzerling, L., Eigentler, T., Fluck, M., Hassel, J. C., Heller-Schenck, D., Leipe, J., Pauschinger, M., Vogel, A., Zimmer, L., & Gutzmer, R. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000491 · Cited by 242
Subphenotypes in critical care: translation into clinical practice
Reddy, K., Sinha, P., O’Kane, C. M., Gordon, A. C., Calfee, C. S., & McAuley, D. F. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30124-7 · Cited by 238
BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
Koya, R. C., Mok, S., Otte, N. J., Blacketor, K. J., Comin-Anduix, B., Tumeh, P. C., Minasyan, A., Graham, N. A., Graeber, T. G., Chodon, T., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2837 · Cited by 234
Self-citationHong, X., Roh, W., Sullivan, R. J., Wong, K. H. K., Wittner, B. S., Guo, H., Dubash, T. D., Sade-Feldman, M., Wesley, B., Horwitz, E. P., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1500 · Cited by 243
Targeting the BRAF V600E Mutation in Multiple Myeloma
Andrulis, M., Lehners, N., Capper, D., Penzel, R., Heining, C., Hüellein, J., Zenz, T., von Deimling, A., Schirmacher, P., Ho, A. D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0014 · Cited by 236
AKT and ERK dual inhibitors: The way forward?
Cao, Z., Liao, Q., Su, M., Huang, K., Jin, J., & Cao, D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.025 · Cited by 244
Waarts, M. R., Stonestrom, A. J., Park, Y. C., & Levine, R. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154943 · Cited by 249
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
Winter, J. M., Yeo, C. J., & Brody, J. R. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23192 · Cited by 234
Girotti, M. R., Gremel, G., Lee, R. J., Galvani, E., Rothwell, D. G., Virós, A., Mandal, A. K., Lim, K. H. J., Saturno, G., Furney, S. J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1336 · Cited by 235
Self-citationEmerging strategies to target RAS signaling in human cancer therapy
Chen, K., Zhang, Y., Qian, L. M., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 247
Yu, H., Steeghs, N., Nijenhuis, C. M., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0137-2 · Cited by 233
Toward precision medicine in glioblastoma: the promise and the challenges
Prados, M. D., Byron, S. A., Tran, N. L., Phillips, J. J., Molinaro, A. M., Ligon, K. L., Wen, P. Y., Kuhn, J. G., Mellinghoff, I. K., de Groot, J., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov031 · Cited by 231
Zimmer, L., Hillen, U., Livingstone, E., Lacouture, M. E., BUSAM, K. J., Carvajal, R. D., Egberts, F., Hauschild, A., Kashani–Sabet, M., Goldinger, S. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.1660 · Cited by 234
Self-citationBoshuizen, J., Koopman, L. A., Krijgsman, O., Shahrabi, A., van den Heuvel, E. G., Ligtenberg, M. A., Vredevoogd, D. W., Kemper, K., Kuilman, T., Song, J.-Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4472 · Cited by 229
Drugging Wnt signalling in cancer
Polakis, P. G. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.126 · Cited by 237
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
Atefi, M. S., von Euw, E., Attar, N., Ng, C., Chu, C., Guo, D., Nazarian, R., Chmielowski, B., Glaspy, J. A., Comin-Anduix, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028973 · Cited by 236
Self-citationHypoxia-activated prodrugs: paths forward in the era of personalised medicine
Hunter, F. W., Wouters, B. G., & Wilson, W. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.79 · Cited by 231
PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective
Cooper, L., Demicco, E. G., Saltz, J. H., Powell, R. T., Rao, A. U. K., & Lazar, A. J. (2017) · The Journal of Pathology · doi:10.1002/path.5028 · Cited by 237
Garbe, C., Peris, K., Hauschild, A., Saïag, P., Middleton, M. R., Spatz, A., Grob, J., Malvehy, J., Newton‐Bishop, J., Stratigos, A., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.013 · Cited by 233
Self-citationComprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma
Lv, H., Liu, X., Zeng, X., Liu, Y., Zhang, C.-J., Zhang, Q., & Xu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.930041 · Cited by 233
“1 months, and the response rates were about 5% (Chapman et al., 2011; Robert et al., 2011).”
BackgroundHaroche, J., Aubart, F. C., & Amoura, Z. (2020) · Blood · doi:10.1182/blood.2019002766 · Cited by 228
Griewank, K., Westekemper, H., Murali, R., Mach, M., Schilling, B., Wiesner, T., Schimming, T. T., Livingstone, E., Sucker, A., Grabellus, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0163 · Cited by 231
Self-citationGreaves, W. O., Verma, S., Patel, K. P., Davies, M. A., Barkoh, B. A., Galbincea, J. M., Yao, H., Lazar, A. J., Aldape, K., Medeiros, L. J., et al. (2012) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.10.002 · Cited by 227
Long, G. V., Eroglu, Z., Infante, J. R., Patel, S. P., DAUD, A. I., Johnson, D. B., Gonzalez, R. C., Kefford, R. F., Hamid, O., Schuchter, L. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.1025 · Cited by 229
Self-citationKinase inhibitors and monoclonal antibodies in oncology: clinical implications
Gharwan, H., & Groninger, H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.213 · Cited by 234
Van Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P.-J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02459 · Cited by 224
Larkin, J., Lao, C. D., Urba, W. J., McDermott, D. F., Horak, C., Jiang, J., & Wolchok, J. D. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1184 · Cited by 223
Self-citationMetastatic Melanoma – A Review of Current and Future Treatment Options
Maverakis, E., Cornelius, L. A., Bowen, G., Phan, T., Patel, F., Fitzmaurice, S., He, Y., Burrall, B. A., Duong, C., Kloxin, A. M., et al. (2014) · Acta Dermato Venereologica · doi:10.2340/00015555-2035 · Cited by 227
Ardekani, G. S., Jafarnejad, S. M., Tan, L., Saeedi, A., & Li, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047054 · Cited by 231
Gonçalvès, A., Gilabert, M., François, É., Dahan, L., Perrier, H., Lamy, R., Ré, D., Largillier, R., Gasmi, M., Tchiknavorian, X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds135 · Cited by 222
Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Chamberlain, M. C., Baik, C. S., Gadi, V. K., Bhatia, S., & Chow, L. Q. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now197 · Cited by 224
Overcoming Immune Evasion in Melanoma
Eddy, K., & Chen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238984 · Cited by 243
Ackerman, A., Klein, O., McDermott, D. F., Wang, W., Ibrahim, N., Lawrence, D. P., Gunturi, A., Flaherty, K. T., Hodi, F. S., Kefford, R. F., et al. (2014) · Cancer · doi:10.1002/cncr.28620 · Cited by 223
Self-citationHaq, R., Yokoyama, S., Hawryluk, E. B., Jönsson, G. B., Frederick, D. T., McHenry, K. T., PORTER, D. A., Tran, T.-N., Love, K. T., Langer, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205575110 · Cited by 229
King, A. J., Arnone, M. R., Bleam, M. R., Moss, K. G., Yang, J., Fedorowicz, K. E., Smitheman, K. N., Erhardt, J. A., Hughes‐Earle, A., Kane-Carson, L. S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067583 · Cited by 228
Woyach, J. A., Bojnik, E., Ruppert, A. S., Stefanovski, M. R., Goettl, V. M., Smucker, K. A., Smith, L. L., Dubovsky, J. A., Towns, W. H., MacMurray, J., et al. (2013) · Blood · doi:10.1182/blood-2013-07-515361 · Cited by 222
Ma, L., Chen, T., Zhang, X., Miao, Y., Tian, X., Yu, K., Xu, X., Niu, Y., Guo, S., Zhang, C., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101801 · Cited by 223
Metadata
- Authors
- Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O'Day, S. J., Sosman, J. A., Kirkwood, J. M., Eggermont, A. M. M., Dreno, B., Nolop, K., Li, J., Nelson, B., Hou, J., Lee, R. J., Flaherty, K. T., & McArthur, G. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Institut Gustave Roussy (FR)
- The Netherlands Cancer Institute (NL)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Royal Marsden Hospital (GB)
- University of Zurich (CH)
- University of Tübingen (DE)
- European Institute of Oncology (IT)
- Tumour Institute of Tuscany (IT)
- University Health Network (CA)
- University of Manchester (GB)
- Hôpital Saint-André (FR)
- Essen University Hospital (DE)
- University of California, Los Angeles (US)
- Angeles Clinic and Research Institute (US)
- Vanderbilt University (US)
- University of Pittsburgh (US)
- Plexxikon (United States) (US)
- Genentech (US)
- Massachusetts General Hospital (US)
- Peter MacCallum Cancer Centre (AU)
- ORCID
- Chapman, Paul B.
- Hauschild, Axel
- Robert, Caroline
- Haanen, John B.
- Ascierto, Paolo
- Larkin, James
- Dummer, Reinhard
- Garbe, Claus
- Testori, Alessandro
- Maio, Michele
- Hogg, David
- Lorigan, Paul
- Jouary, Thomas
- Schadendorf, Dirk
- Ribas, Antoni
- O'Day, Steven J.
- Sosman, Jeffrey A.
- Kirkwood, John M.
- Eggermont, Alexander M.M.
- Li, Jiang
- Hou, Jeannie
- Lee, Richard J.
- Flaherty, Keith T.
- McArthur, Grant A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-06-30
- Volume
- 364
- Issue
- 26
- Pages
- 2507-2516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3549296
- OpenAlex
- W2128542677
- Cited by
- 7,720
- References
- 28
- Citations by year
- 2026: 141 · 2025: 187 · 2024: 265 · 2023: 276 · 2022: 401 · 2021: 377 · 2020: 423 · 2019: 470 · 2018: 496 · 2017: 613 · 2016: 660 · 2015: 829 · 2014: 844 · 2013: 865 · 2012: 693
- FWCI
- 332.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institutes of Health (UL1TR000005)
- National Cancer Institute (K24CA097588)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, dacarbazine, metastatic melanoma, BRAF V600E mutation, BRAF inhibitors, overall survival, progression-free survival, drug toxicity, keratoacanthoma, photosensitivity
- MeSH terms
- Vemurafenib, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Sulfonamides, Survival Analysis, Disease-Free Survival, Proto-Oncogene Proteins B-raf, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
